StreetInsider.com News Articles

QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak

Wed, 15 Jul 2026 16:05:00 -0400

More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May 2026 as infections linked to the foodborne parasite Cyclospora continue to rise nationwide

QIAGEN’s FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 can detect Cyclospora infections in about an hour as part of a 16-target gastrointestinal pathogens menu

QIAGEN also offers QIAcuity digital PCR and QIAseq next-generation sequencing tools for research and public health investigations

GERMANTOWN, Md., & VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today highlighted its portfolio of molecular testing solutions supporting the public health response to the growing number of cyclosporiasis

QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak

Wed, 15 Jul 2026 16:05:00 -0400

More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May 2026 as infections linked to the foodborne parasite Cyclospora continue to rise nationwide

QIAGEN’s FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 can detect Cyclospora infections in about an hour as part of a 16-target gastrointestinal pathogens menu

QIAGEN also offers QIAcuity digital PCR and QIAseq next-generation sequencing tools for research and public health investigations

QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak

Wed, 15 Jul 2026 16:05:00 -0400

More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May 2026 as infections linked to the foodborne parasite Cyclospora continue to rise nationwide

QIAGEN’s FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 can detect Cyclospora infections in about an hour as part of a 16-target gastrointestinal pathogens menu

QIAGEN also offers QIAcuity digital PCR and QIAseq next-generation sequencing tools for research and public health investigations

QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak

Wed, 15 Jul 2026 16:05:00 -0400

More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May 2026 as infections linked to the foodborne parasite Cyclospora continue to rise nationwide

QIAGEN’s FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 can detect Cyclospora infections in about an hour as part of a 16-target gastrointestinal pathogens menu

QIAGEN also offers QIAcuity digital PCR and QIAseq next-generation sequencing tools for research and public health investigations

QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak

Wed, 15 Jul 2026 16:05:00 -0400

More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May 2026 as infections linked to the foodborne parasite Cyclospora continue to rise nationwide

QIAGEN’s FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 can detect Cyclospora infections in about an hour as part of a 16-target gastrointestinal pathogens menu

QIAGEN also offers QIAcuity digital PCR and QIAseq next-generation sequencing tools for research and public health investigations

QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak

Wed, 15 Jul 2026 16:05:00 -0400

More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May 2026 as infections linked to the foodborne parasite Cyclospora continue to rise nationwide

QIAGEN’s FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 can detect Cyclospora infections in about an hour as part of a 16-target gastrointestinal pathogens menu

QIAGEN also offers QIAcuity digital PCR and QIAseq next-generation sequencing tools for research and public health investigations

QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast

Wed, 15 Jul 2026 08:48:00 -0400

VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2026.

Press release date / time: Wednesday, August 5 shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.

Conference call date / time: Thursday, August 6, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time.

Three options for joining the conference call

Register for call back connection - Click here: Connect me
Service is available 15 minutes before the call starts

Dial-in by

QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast

Wed, 15 Jul 2026 08:48:00 -0400

VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2026.
Press release date / time: Wednesday, August 5 shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.
Conference call date / time: Thursday, August 6, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time.
Three options for joining the conference call
Register for call back connection - Click here: Connect me
Service is available 15 minutes before the call starts
Dial-in by

QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast

Wed, 15 Jul 2026 08:48:00 -0400

VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2026.
Press release date / time: Wednesday, August 5 shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.
Conference call date / time: Thursday, August 6, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time.
Three options for joining the conference call
Register for call back connection - Click here: Connect me
Service is available 15 minutes before the call starts
Dial-in by

QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast

Wed, 15 Jul 2026 08:48:00 -0400

VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2026.
Press release date / time: Wednesday, August 5 shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.
Conference call date / time: Thursday, August 6, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time.
Three options for joining the conference call
Register for call back connection - Click here: Connect me
Service is available 15 minutes before the call starts
Dial-in by

QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast

Wed, 15 Jul 2026 08:48:00 -0400

VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2026.
Press release date / time: Wednesday, August 5 shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.
Conference call date / time: Thursday, August 6, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time.
Three options for joining the conference call
Register for call back connection - Click here: Connect me
Service is available 15 minutes before the call starts
Dial-in by

QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast

Wed, 15 Jul 2026 08:48:00 -0400

VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2026.
Press release date / time: Wednesday, August 5 shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.
Conference call date / time: Thursday, August 6, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time.
Three options for joining the conference call
Register for call back connection - Click here: Connect me
Service is available 15 minutes before the call starts
Dial-in by

QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe

Tue, 14 Jul 2026 16:05:00 -0400

New CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance markers from positive blood cultures

Together with the BCID GPF Plus AMR Panel, QIAstat-Dx now detects 33 pathogen targets and 28 antimicrobial resistance markers for comprehensive bloodstream infection testing

QIAstat-Dx delivers results in about one hour to support patient management, antimicrobial stewardship and infection control efforts

Builds on comprehensive offering for respiratory, gastrointestinal and meningitis / encephalitis panels as R&D continues on further menu expansion

VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the

QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe

Tue, 14 Jul 2026 16:05:00 -0400

New CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance markers from positive blood cultures

Together with the BCID GPF Plus AMR Panel, QIAstat-Dx now detects 33 pathogen targets and 28 antimicrobial resistance markers for comprehensive bloodstream infection testing

QIAstat-Dx delivers results in about one hour to support patient management, antimicrobial stewardship and infection control efforts

Builds on comprehensive offering for respiratory, gastrointestinal and meningitis / encephalitis panels as R&D continues on further menu expansion

VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the

QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe

Tue, 14 Jul 2026 16:05:00 -0400

New CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance markers from positive blood cultures

Together with the BCID GPF Plus AMR Panel, QIAstat-Dx now detects 33 pathogen targets and 28 antimicrobial resistance markers for comprehensive bloodstream infection testing

QIAstat-Dx delivers results in about one hour to support patient management, antimicrobial stewardship and infection control efforts

Builds on comprehensive offering for respiratory, gastrointestinal and meningitis / encephalitis panels as R&D continues on further menu expansion

VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the

QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe

Tue, 14 Jul 2026 16:05:00 -0400

New CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance markers from positive blood cultures

Together with the BCID GPF Plus AMR Panel, QIAstat-Dx now detects 33 pathogen targets and 28 antimicrobial resistance markers for comprehensive bloodstream infection testing

QIAstat-Dx delivers results in about one hour to support patient management, antimicrobial stewardship and infection control efforts

Builds on comprehensive offering for respiratory, gastrointestinal and meningitis / encephalitis panels as R&D continues on further menu expansion

VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the

QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe

Tue, 14 Jul 2026 16:05:00 -0400

New CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance markers from positive blood cultures

Together with the BCID GPF Plus AMR Panel, QIAstat-Dx now detects 33 pathogen targets and 28 antimicrobial resistance markers for comprehensive bloodstream infection testing

QIAstat-Dx delivers results in about one hour to support patient management, antimicrobial stewardship and infection control efforts

Builds on comprehensive offering for respiratory, gastrointestinal and meningitis / encephalitis panels as R&D continues on further menu expansion

VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the

QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe

Tue, 14 Jul 2026 16:05:00 -0400

New CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance markers from positive blood cultures

Together with the BCID GPF Plus AMR Panel, QIAstat-Dx now detects 33 pathogen targets and 28 antimicrobial resistance markers for comprehensive bloodstream infection testing

QIAstat-Dx delivers results in about one hour to support patient management, antimicrobial stewardship and infection control efforts

Builds on comprehensive offering for respiratory, gastrointestinal and meningitis / encephalitis panels as R&D continues on further menu expansion

VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the

QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe

Tue, 14 Jul 2026 16:05:00 -0400

New CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance markers from positive blood cultures

Together with the BCID GPF Plus AMR Panel, QIAstat-Dx now detects 33 pathogen targets and 28 antimicrobial resistance markers for comprehensive bloodstream infection testing

QIAstat-Dx delivers results in about one hour to support patient management, antimicrobial stewardship and infection control efforts

Builds on comprehensive offering for respiratory, gastrointestinal and meningitis / encephalitis panels as R&D continues on further menu expansion

VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the

QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe

Tue, 14 Jul 2026 16:05:00 -0400

New CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance markers from positive blood cultures

Together with the BCID GPF Plus AMR Panel, QIAstat-Dx now detects 33 pathogen targets and 28 antimicrobial resistance markers for comprehensive bloodstream infection testing

QIAstat-Dx delivers results in about one hour to support patient management, antimicrobial stewardship and infection control efforts

Builds on comprehensive offering for respiratory, gastrointestinal and meningitis / encephalitis panels as R&D continues on further menu expansion

VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the

QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe

Tue, 14 Jul 2026 16:05:00 -0400

New CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance markers from positive blood cultures

Together with the BCID GPF Plus AMR Panel, QIAstat-Dx now detects 33 pathogen targets and 28 antimicrobial resistance markers for comprehensive bloodstream infection testing

QIAstat-Dx delivers results in about one hour to support patient management, antimicrobial stewardship and infection control efforts

Builds on comprehensive offering for respiratory, gastrointestinal and meningitis / encephalitis panels as R&D continues on further menu expansion

VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the

QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe

Tue, 14 Jul 2026 16:05:00 -0400

New CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance markers from positive blood cultures

Together with the BCID GPF Plus AMR Panel, QIAstat-Dx now detects 33 pathogen targets and 28 antimicrobial resistance markers for comprehensive bloodstream infection testing

QIAstat-Dx delivers results in about one hour to support patient management, antimicrobial stewardship and infection control efforts

Builds on comprehensive offering for respiratory, gastrointestinal and meningitis / encephalitis panels as R&D continues on further menu expansion

VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the

QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma

Mon, 15 Jun 2026 01:30:00 -0400

Planned gene expression assay launches and high-multiplex capabilities are expected to expand QIAcuity into one of the largest molecular biology application areas

Expanded Cell and Gene Therapy offerings and workflow automation capabilities strengthen the QIAcuity digital PCR ecosystem

New software capabilities support standardized analysis and reporting across digital PCR workflows

VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its QIAcuity digital PCR (dPCR) ecosystem, with a focus on expanding gene expression capabilities, broadening assay content and enhancing workflow standardization to support the growing adoption of dPCR

QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma

Mon, 15 Jun 2026 01:30:00 -0400

Planned gene expression assay launches and high-multiplex capabilities are expected to expand QIAcuity into one of the largest molecular biology application areas

Expanded Cell and Gene Therapy offerings and workflow automation capabilities strengthen the QIAcuity digital PCR ecosystem

New software capabilities support standardized analysis and reporting across digital PCR workflows

VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its QIAcuity digital PCR (dPCR) ecosystem, with a focus on expanding gene expression capabilities, broadening assay content and enhancing workflow standardization to support the growing adoption of dPCR

QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma

Mon, 15 Jun 2026 01:30:00 -0400

Planned gene expression assay launches and high-multiplex capabilities are expected to expand QIAcuity into one of the largest molecular biology application areas

Expanded Cell and Gene Therapy offerings and workflow automation capabilities strengthen the QIAcuity digital PCR ecosystem

New software capabilities support standardized analysis and reporting across digital PCR workflows

VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its QIAcuity digital PCR (dPCR) ecosystem, with a focus on expanding gene expression capabilities, broadening assay content and enhancing workflow standardization to support the growing adoption of dPCR